SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as investors discuss the potential impact of a reported earnings miss, attributed to a tax dispute in Brazil, despite revenue being in line with expectations. Community members are debating whether this dip presents a buying opportunity or signals a larger correction for the streaming giant, with some questioning the company's valuation and future growth prospects in an increasingly competitive market.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including from sellers, advertising, and subscription services through internationally-focused online stores. The AWS segment is composed of global sales of compute, storage, database, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

Amazon's stock is experiencing volatility as traders discuss the impact of a widespread AWS outage and its potential fallout, including possible lawsuits. The community is also weighing the implications of Anthropic choosing Google over Amazon for cloud computing needs, sparking debate about AWS's competitive positioning against $MSFT and $GOOGL. Despite these concerns, some investors view the dip as a buying opportunity, citing Amazon's strong market presence.

Cipher Mining, Inc. operates as a Bitcoin mining ecosystem in the United States. The firm is developing a cryptocurrency business. The company was founded in 2021 and is headquartered in New York, NY.

Cipher Mining Inc

CIFR is trending due to a sector-wide selloff, sparking debates about potential manipulation and overbought conditions; the community is weighing whether this dip presents a buying opportunity, or signals further declines. Discussions also involve upcoming earnings and speculation around potential deals, particularly concerning AI data centers. Some traders are expressing concerns about dilution and the stock's correlation with Bitcoin's volatility.

IREN Ltd. is a vertically integrated data center business powering the future of Bitcoin, AI and beyond with renewable energy. It is strategically located in renewable-rich, fiber-connected regions across the US and Canada. IREN’s large-scale, grid-connected facilities are purpose-built for the next generation of power-dense computing applications. The company was founded by Daniel Roberts and William Roberts on November 6, 2018, and is headquartered in Sydney, Australia.

IREN Ltd.

IREN Limited

IREN is experiencing a selloff, prompting discussions about potential manipulation and profit-taking after a significant run-up, with some community members pointing to broader sector weakness as a factor; despite the dip, bulls remain confident in the long-term prospects of IREN given its position in AI and data centers, while others express concerns over short-term volatility.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

GOOGL is trending as investors assess the potential impact of OpenAI's browser and Google's AI initiatives, including a significant investment in Indian infrastructure. Community discussions revolve around whether the stock's recent pullback represents a buying opportunity amidst the evolving AI landscape and competition in search.

Alphabet Inc - Ordinary Shares - Class C

GOOG is trending as investors discuss its AI strategy and potential partnerships, including rumored collaborations with Anthropic. Community talking points highlight Google's AI capabilities, such as Gemini, DeepMind, and GCP, emphasizing the company's potential to dominate the AI landscape. Broader discussions cover capital expenditures on data centers and a generally positive outlook on the stock's valuation relative to peers.

Intuitive Surgical, Inc. engages in the provision of robotic-assisted surgical solutions and invasive care through a comprehensive ecosystem of products and services. Its products include Da Vinci Surgical and Ion Endoluminal systems. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.

Intuitive Surgical Inc

Intuitive Surgical is trending following its earnings report, with community chatter focused on procedure growth and the company's future outlook. While some express optimism about the robotic surgery market and potential for new all-time highs, others are concerned about margin pressures and valuation. Discussions also revolve around the impact of tariffs and expansion into international markets.

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is trending following its acquisition of Railbird, a prediction market platform, signaling a strategic move into regulated prediction markets beyond sports betting, stirring debate about its potential impact on DraftKings' standing with OSB states. The community is discussing whether this acquisition is a bold move towards sustainable growth or a reaction to competition, particularly from prediction markets like Polymarket and Kalshi, and its potential implications for expansion into untapped markets like California and Texas. Additionally, DraftKings' stock performance is being weighed against competitors like Robinhood, influencing community sentiment and investment strategies.

Texas Instruments Incorporated engages in the design and manufacture of semiconductors. It operates through the following segments: Analog, Embedded Processing, and Other. The Analog segment semiconductors change real-world signals, such as sound, temperature, pressure or images, by conditioning them, amplifying them and often converting them to a stream of digital data that can be processed by other semiconductors, such as embedded processors. The Embedded Processing segment involves handling specific tasks and can be optimized for various combinations of performance, power, and cost, depending on the application. The company was founded in 1930 and is headquartered in Dallas, TX.

Texas Instruments Inc.

Texas Instruments is trending following its earnings report and subsequent guidance, which has led to significant discussion about the company's near-term outlook. Community members are debating whether the stock is oversold, with some pointing to broader sector concerns and potential trade tensions affecting future performance. Others suggest the dip presents a buying opportunity, citing the company's long-term fundamentals and dividend.

Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of a portfolio of product candidates to treat central nervous system diseases. It develops Roluperidone for the treatment of negative symptoms in patients with schizophrenia and MIN-301 for the treatment of Parkinson’s disease. The company was founded by Rogerio Vivaldi Coelho and Goeffrey Robin Race on April 23, 2007 and is headquartered in Burlington, MA.

Minerva Neurosciences Inc

Minerva Neurosciences ($NERV) is trending after securing significant funding to advance its schizophrenia treatment, sparking enthusiastic discussion among investors. The community is focused on the potential for FDA approval and the stock's low float, while also debating the possibility of dilution and short squeezes. The stock's surge is being viewed in the context of the broader biotech sector and its potential for high-reward plays.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Activist investor Jana Partners has quietly built a stake in Cooper Cos. and reportedly plans to push the California-based medical device maker to explore strategic alternatives, including a potential merger between its contact-lens business and rival Bausch + Lomb.The size of Jana’s stake has not been disclosed, but the investor is apparently preparing to engage with Cooper’s management to influence direction, The Wall Street Journal&nbsp;<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.wsj.com/business/deals/activist-jana-takes-stake-in-cooper-a-maker-of-medical-devices-20ffbe9c?mod=hp_lead_pos6">reported</a>,&nbsp;citing people familiar with the matter.Bausch + Lomb CEO Brent Saunders, known for his aggressive dealmaking, said he would be open to such a combination, and that it could “strengthen competition and create a more scaled company in the contact-lens segment.”Pressure To Improve Returns&nbsp;Beyond pushing for a merger, Jana Partners also&nbsp;reportedly wants Cooper to take a hard look at how it’s running the business. The activist investor plans to press the company to use its capital more efficiently and deliver stronger returns for shareholders, according to people familiar with the matter.Jana believes Cooper’s two main units, including CooperVision, which makes contact lenses, and CooperSurgical, focused on women’s health and fertility, don’t really fit together and have little overlap and simplifying the structure could improve the company’s performance.Cooper’s DeclineCooper, valued at about $14 billion, reported $3.9 billion in revenue for 2024, with the CooperVision segment contributing over two-thirds of total sales.The firm reportedly maintains that it remains confident in its dual-market strategy, arguing that both segments operate in growing global markets and complement each other strategically.However, Cooper’s contact-lens business has lagged rivals,&nbsp;according to the report, while its women’s health segment has faced margin pressure after a series of acquisitions that have yet to deliver returns.Why Bausch + Lomb Fits Into the PictureJana believes there are potential buyers for both Cooper divisions, but sees a tie-up between CooperVision and Bausch + Lomb as particularly appealing to investors.Bausch + Lomb, with a market capitalization of about $5.3 billion, was itself spun out from a larger healthcare company under Saunders’s leadership. Both firms compete with Johnson &amp; Johnson and Alcon in the global contact-lens market, and a merger could create a stronger challenger in the space.Jana’s Track Record in ActivismJana has a history of driving corporate shake-ups. It previously pushed for strategic reviews at Frontier Communications, which was later acquired by Verizon, and Markel, which is still under review.Earlier this year, Jana struck an agreement with Lamb Weston, the frozen potato giant, leading to the addition of six new board members after the activist pressed for changes.How Is Stocktwits Reading The Mood?On Stocktwits, retail sentiment was ‘bullish’ for Cooper and ‘bearish’ for Bausch + Lomb, with overall message volume remaining ‘low’ for both.While&nbsp;<a href="https://stocktwits.com/symbol/COO">Cooper Cos.’ stock</a> has declined 22% so far this year,&nbsp;<a href="https://stocktwits.com/symbol/BLCO">Bausch + Lomb’s stock</a> has fallen 17% over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Activist Investor Turns Up Heat On Cooper, Urges Bausch + Lomb Merger To Boost Returns: Report

Jana Partners is urging Cooper to improve capital use and returns, saying its contact-lens and women’s health units lack strategic fit and drag on performance.

Equity

BLCO vs. DHR: Which Stock Should Value Investors Buy Now?

BLCO vs. DHR: Which Stock Is the Better Value Option?

Bausch + Lomb (BLCO) Reports Q2 Earnings: What Key Metrics Have to Say

Although the revenue and EPS for Bausch + Lomb (BLCO) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

Bausch + Lomb (BLCO) Q2 Earnings and Revenues Surpass Estimates

Bausch + Lomb (BLCO) delivered earnings and revenue surprises of +16.67% and +2.37%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

New Strong Sell Stocks for July 30th

ACHC, BLCO and BBCP have been added to the Zacks Rank #5 (Strong Sell) List on July 30, 2025.

New Strong Sell Stocks for July 24th

COMP, EKTAY and BLCO have been added to the Zacks Rank #5 (Strong Sell) List on July 24, 2025.

Analysts Estimate Bausch + Lomb (BLCO) to Report a Decline in Earnings: What to Look Out for

Bausch + Lomb (BLCO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

WF downgrades Bausch + Lomb on enVista recall giving a near-term uncertainty

Investing.com -- Wells Fargo downgraded Bausch + Lomb Corp to Equal Weight from Overweight on uncertainty from the voluntary recall of its enVista intraocular lenses (IOLs), which is expected to weigh on sales growth, earnings, and investor sentiment. Brokerage cut its price target to $15 from $24, based on 9.5x its 2026 EBITDA estimate of $1.0 billion.

Bausch Health Companies Inc. shares (BHC) jumped over 7% in after-hours trading on Wednesday following a solid fourth-quarter earnings report that beat revenue estimates and reaffirmed strong guidance for 2025.The company posted Q4 revenue of $2.56 billion, surpassing the consensus estimate of $2.51 billion, while adjusted earnings per share (EPS) of $1.14 narrowly topped expectations of $1.13.&nbsp;Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) came in at $935 million, up from $869 million a year ago.CEO Thomas Appio highlighted 2024 as a year of "delivering on our commitments," with results landing at the high end of revenue guidance and exceeding expectations for adjusted EBITDA (excluding Bausch + Lomb) and operating cash flow.Salix, the company's gastrointestinal and hepatology division, generated $634 million in Q4 revenue, up 9% year-over-year. This was largely driven by Xifaxan, a treatment for irritable bowel syndrome and traveler's diarrhea, which posted 16% growth.&nbsp;The Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.For 2025, Bausch Health projects revenue between $9.90 billion and $10.15 billion, above the consensus estimate of $9.89 billion.&nbsp;The company also forecasts FY25 adjusted EBITDA between $3.525 billion and $3.675 billion.<figure class="image"><img style="aspect-ratio:1318/324;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/BHC_sentiment_and_message_volume_Feb_19_07562dbe77.png" alt="BHC sentiment and message volume Feb 19.png" width="1318" height="324"><figcaption>BHC sentiment and message volume Feb 19 | source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits turned 'extremely bullish' following the earnings report, with message volume spiking 1,900% on Wednesday.One user highlighted "very good organic revenue growth and solid guidance," expecting a strong bounce for the stock.&nbsp;Another hoped for a rally past $20 per share.<stembedurl>https://stocktwits.com/Neildc/message/604885428</stembedurl><stembedurl>https://stocktwits.com/Maxgluteal/message/604910108</stembedurl>However, BHC shares remain about 35% below analysts' average target price of $8.83.&nbsp;The stock has lost over 19% year-to-date.&nbsp;&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Bausch Health Stock Pops After-Hours On Q4 Earnings Beat, Bullish Outlook: Retail Confidence Rises

The company’s Solta segment, which includes medical aesthetics, saw Q4 revenue climb 34% to $138 million, fueled by strong demand in South Korea and China.

Bausch & Lomb to shake up contact lenses with deal off the table

Bausch & Lomb said this month it had explored taking the company private with a third-party buyer. No deal was reached as a consortium of private equity firms TPG and Blackstone reportedly backed...

Bausch + Lomb Corp. develops, manufactures, and markets eye health products. It offers over-the-counter supplements, eye care products, ophthalmic pharmaceuticals, contact lenses, lens care, ophthalmic surgical devices, and instruments. The company operates its business through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals and Surgical. The Vision Care/Consumer Health Care segment includes both contact lens and consumer eye care businesses. The Ophthalmic Pharmaceuticals segment consists of a broad line of proprietary pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. The Surgical segment consists of medical device equipment, consumables and instrumental tools and technologies for the treatment of corneal, cataracts, and vitreous and retinal eye conditions, and includes IOLs and delivery systems, phacoemulsification equipment and other surgical instruments and devices necessary for cataract surgery. Bausch + Lomb was founded by John Jacob Bausch and Henry Lomb in 1853 and is headquartered in Vaughan, Canada.

Bausch + Lomb Corp

Will Netflix ($NFLX) beat quarterly earnings? 
 
*Powered by Polymarket

Stocktwits

) beat quarterly earnings? 
 
*Powered by Polymarket

Current Price	$15.63
Prev Close	$15.75
Open	$15.71
Dividend Yield	0.00%
50-Day Moving Average	$14.79
Beta	1.08
Avg. Volume	537,662.62
PE Ratio	-20.36

52-Week High	$20.94
52-Week Low	$10.45
Market Capitalization	$5.57B
EPS (Annual)	-$0.9011
Price to Book	0.87
Revenue Per Employee	$354,888.89
Enterprise Value/EBITDA	N/A

BLCO
Bausch + Lomb Corp.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLCO News

BLCOBausch + Lomb Corp.